6 Recommendations for further research

6.1 A phase III trial of entecavir plus tenofovir disoproxil combination therapy versus entecavir monotherapy in treatment-naive people with chronic hepatitis B is currently recruiting participants.

6.2 Research on the long-term risk of resistance with tenofovir disoproxil monotherapy and tenofovir disoproxil in combination with other antiviral agents is needed because few RCTs are currently available.

  • National Institute for Health and Care Excellence (NICE)